A novel series of CXCR4 antagonists with piperidinyl and piperazinyl alkylamine side chains designed as butyl amine replacements are described. Several of these compounds showed similar activity to the parent compound TIQ-15 () in a SDF-1 induced calcium flux assay. Preliminary structure-activity relationship investigations led us to identify a series containing -propyl piperazine side chain analogs exemplified by with improved off-target effects as measured in a muscarinic acetylcholine receptor (mAChR) calcium flux assay and in a limited drug safety panel screen. Further efforts to explore SAR and optimize drug properties led to the identification of the '-ethyl--propyl-piperazine tetrahydroisoquinoline derivative and the -propyl-piperazine benzimidazole compound , which gave the best overall profiles with no mAChR or CYP450 inhibition, good permeability in PAMPA assays, and metabolic stability in human liver microsomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949813 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.8b00030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aripiprazole-loaded niosome/chitosan-gold nanoparticles for breast cancer chemo-photo therapy.
BMC Biotechnol
December 2024
Department of Microbiology, Faculty of Veterinary and Agriculture, Islamic Azad University, Shabestar Branch, Shabestar, Iran.
Introduction: Breast cancer, a formidable global health challenge for women, necessitates innovative therapeutic strategies with enhanced efficacy and minimal side effects. Aripiprazole (ARI), a widely used schizophrenia medication, exhibits promising potential in the treatment of breast cancer. As cancer therapy evolves towards a combination approach, multimodal nano-based delivery systems, such as ARI-loaded niosomes (NIOs) combined with Chitosan-Au nanoparticles for chemo-photothermal therapy, show promise over traditional chemotherapy alone by enhancing targeted efficacy and minimizing side effects.
View Article and Find Full Text PDFHaematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review.
Ann Med
December 2025
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE.
Article Synopsis
- PARP inhibitors like Olaparib are important in treating cancers linked to BRCA mutations, but they can cause significant side effects, particularly hematologic toxicities such as anemia.
- A study in the UAE reviewed medical charts of 66 patients on Olaparib, finding that 70.8% developed anemia and about one-third experienced neutropenia and thrombocytopenia, with nearly half requiring blood transfusions.
- The research underscores the need for awareness of these adverse effects and suggests further studies to improve management strategies for patients on Olaparib to reduce hematologic complications.
"If they take it without knowing, they will default…": perceptions of targeted information transfer to promote adherence to intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy in western Kenya.
Malar J
November 2024
Disease Control Department, London School of Hygiene and Tropical Medicine, London, UK.
Background: Increasing resistance to sulfadoxine-pyrimethamine (SP) threatens the effectiveness of intermittent preventive treatment (IPTp) to prevent malaria in pregnancy. Dihydroartemisinin-piperaquine (DP) is the most promising candidate to emerge from clinical trials, but requires a multi-day regimen. Despite being a single-dose regimen, coverage of IPTp-SP remains low, fuelling concerns about adherence to multi-day drug options.
View Article and Find Full Text PDFIdentification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico.
Eur J Med Chem
January 2025
College of Chemistry and Life Science, Beijing University of Technology, Beijing, 100124, PR China.
The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation is a key target for acute myeloid leukemia (AML) treatment. The second-generation inhibitors such as Gilteritinib still present off-target effects and associated side effects. Therefore, identifying novel FLT3-ITD inhibitors has become a promising strategy for AML treatment.
View Article and Find Full Text PDFComputational Investigation of the Therapeutic Potential of in the Management of Erectile Dysfunction.
Int J Mol Sci
November 2024
Phytomedicine, Biochemical Toxicology and Biotechnology Research Laboratories, Department of Biochemistry, College of Sciences, Afe Babalola University, PMB 5454, Ado-Ekiti 360001, Nigeria.
Erectile dysfunction (ED) is a multifactorial social problem affecting men worldwide. While phosphodiesterase type 5 inhibitors (PDE5) like sildenafil are commonly used, they often present side effects, underscoring the need for alternative therapies. Therefore, this study investigated the potential of phytochemicals from in the management of ED.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!